Global Endoscopy Visualization Systems Pipeline Report 2022: Create Effective Counter Strategies to Gain Competitive Advantage – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Endoscopy Visualization Systems Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. Scope of the report Extensive coverage of the Endoscopy Visualization Systems under development The report reviews details of major pipeline products which includes, product description, licensing … [Read more…]

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer

FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy LLC, a clinical-stage interventional oncology drug company, announced enrollment is complete in a Phase 2a trial of intratumoral (IT) large surface area microparticle paclitaxel (LSAM-PTX) with standard of care (SOC) therapy in patients with nonoperable lung cancer. The single arm trial (NCT04314895) enrolled 18 subjects at four clinical sites with primary … [Read more…]

Asia Pacific Precision Diagnostics Market Report 2022: Surging Demand for Personalized Medicine Drives Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Precision Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type, Application, and End User” report has been added to ResearchAndMarkets.com’s offering. The precision diagnostics market in Asia Pacific is expected to grow from US$ 15,157.61 million in 2022 to US$ 33,007.52 million by 2028. It is … [Read more…]

European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies

− LIVTENCITY Is the First and Only Treatment Approved for This Indication by the EC1 − CMV Is One of the Most Common and Serious Post-transplant Infections and Can Lead to Loss of Transplanted Organ and Failure of Graft 2,3 OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) has … [Read more…]

Rallybio Announces Pricing of $50 Million Public Offering

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares of … [Read more…]

Kirin Holdings and Kao Begin Joint Research On The Relationship Between Visceral Fat and Immunology

TOKYO–(BUSINESS WIRE)–Kirin Holdings Company, Limited (Kirin Holdings) and Kao Corporation (Kao) will participate in the “Wakayama Health Promotion Study” cohort study*1 led by Wakayama Medical University and compiled by the Health Promotion Research Center (HPRC), a non-profit organization, from this month. Kirin Holdings and Kao will jointly conduct research to investigate the relationship between visceral … [Read more…]

Elysian Wellness: Veteran Owned Ketamine Clinic Celebrates 1-Year Anniversary

VIRGINIA BEACH, Va.–(BUSINESS WIRE)–On Tuesday, October 25th, Elysian Wellness celebrated its one year anniversary. Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain. Elysian Wellness is the only practice in Hampton Roads that is run exclusively … [Read more…]

Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study

Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine announced data validating the clinical utility of the company’s PrismRA test for guiding treatment selection for rheumatoid arthritis (RA) patients. The latest publication in the … [Read more…]

Tandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

SAN DIEGO–(BUSINESS WIRE)–$TNDM #TNDM–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.1 Presented today at the … [Read more…]

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median duration of response of 26.6 months, a 53% CR rate at 24 months and a safety profile comparable to BCG alone This novel IL-15 superagonist N-803 – referred to as nogpendekin alfa inbakicept (NAI) in the … [Read more…]